Back to home

About the research

Can a GP-led model of diabetes care, supported by specialists and diabetes educators, work under real rural conditions?

eCARE — Enhanced Care through Case Conferencing and Remote Engagement — is a NSW Health funded translational research trial. It tests whether a diabetes optimisation model developed over a decade by Western Sydney Diabetes can be translated and sustained in Western NSW, delivered through general practices rather than around them. It is time-limited, not a new routine service: the point is to generate the evidence for future decisions about scale and recurrent funding.

The rural NSW context

Rural and regional NSW has capable general practice teams and a high level of diabetes need, with limited local specialist support to draw on. Three constraints, all structural:

Too few specialists

Expertise has to be shared with general practice differently, because there are not enough rural endocrinologists to see everyone.

Fragmented care

Episodic referrals and disconnected consultations leave little room for preparation, shared decisions or follow-up.

Funding that fights it

Team-based chronic disease care takes time and coordination that current arrangements barely pay for.

Who you would be working with

Prof. Glen Maberly

Prof. Glen Maberly

Endocrinologist · Coordinating Principal Investigator

Endocrinologist and director of Western Sydney Diabetes, leading the eCARE program and chairing its clinical safety oversight.

Dr Rajini Jayaballa

Dr Rajini Jayaballa

Endocrinologist · Investigator

Endocrinologist with Western Sydney Diabetes, providing specialist input to case conferences and clinical guidance for participating practices.

Prof. Ted Wu

Prof. Ted Wu

Endocrinologist · MetaDiab

Provides specialist case-conference support and clinical expertise to GP teams taking part in eCARE.

Prof. Jencia Wong

Prof. Jencia Wong

Endocrinologist · Investigator, MetaDiab

Senior endocrinologist bringing specialist diabetes expertise to eCARE's case conferencing and provider education.

Study design

A cluster-randomised, stepped-wedge trial running over 18 months, opening with an eight-week phased implementation period in which practices complete Good Clinical Practice and protocol training. The design allows outcomes to be compared over time without a parallel control group — and without displacing existing services.

12

general practices taking part

~20

participants per practice

18

months, four stepped groups

HbA1c

primary outcome measure

How the trial rolls out

eCARE uses a stepped-wedge design: practices are grouped and each group starts the intervention at a different point, 8 weeks apart. Every practice ends up receiving the full intervention — none miss out.

Group
Period 1
Period 2
Period 3
Period 4
Group 1
Intervention
Intervention
Intervention
Intervention
Group 2
Control
Intervention
Intervention
Intervention
Group 3
Control
Control
Intervention
Intervention
Group 4
Control
Control
Control
Intervention
Standard care (control) eCARE intervention

The intervention: a three-phase care package

Structured, time-limited and focused on skill transfer — anchored throughout in the GP–patient relationship.

Phase 1

Preparation and activation

Structured referral, pathology, short-term CGM, app onboarding and clarification of patient priorities. The first case conference is booked within the first eight weeks.

Phase 2 · 0–4 months

Case conferencing and optimisation

GP-led virtual case conferencing with endocrinologist and diabetes educator input, supported by intermittent CGM and digital coaching, with as many touchpoints as the patient needs.

Phase 3 · 4–6 months

Consolidation and transition

Follow-up conferences and, with the Western Diabetes Hub and the GP, a co-developed transition plan ensuring a supported return to routine GP-led management.

What the trial measures

Patient outcomes

  • HbA1c, glucose, lipids and kidney measures
  • Quality of life and diabetes distress
  • BMI, blood pressure and medications
  • Hospital and healthcare use

Practice outcomes

  • Case conference, CGM and Diabetes Together uptake
  • Diabetes-care and screening indicators
  • Practice-level HbA1c
  • Team capability and confidence

Qualitative evaluation

  • Interviews with patients, GPs, staff and partners
  • Implementation and acceptability
  • Cultural safety and local leadership
  • Led by the Sydney Health Literacy Lab, University of Sydney

Economic evaluation

  • Implementation cost
  • Cost-effectiveness
  • Healthcare utilisation
  • Whether reimbursement levels sustain participation

The evidence so far

Three steps: the model was tested and published in Western Sydney, then trialled informally across Western NSW, and is now being evaluated formally here.

1

It worked in Western Sydney, and the results are published

A retrospective cohort study of 103 people with type 2 diabetes who went through virtual case conferencing with CGM found average HbA1c fell from 9.6% to 8.2% (a 1.4 point reduction, 95% CI 1.03–1.82, P<.001), time in range rose from 46% to 73% (P<.001), and the glucose management indicator improved from 7.9% to 7.0% (P<.001) — all within three to four months. Total daily insulin dose did not change significantly, indicating more targeted management rather than simply more medication.

Mahfuza U, Meyerowitz-Katz G, Rasheed RA, Dick H, Maberly G, Jayaballa R. Digital innovation and integrated care in people with diabetes in Western Sydney: retrospective cohort study. JMIR Diabetes 2025;10:e64832. doi:10.2196/64832

2

Western NSW clinicians have already tried it

A year of staged orientation with the Western NSW Local Health District and Primary Health Network preceded the trial: preparatory case conferencing with about ten practices and forty patients, which shaped the design, and a Dubbo Masterclass in June 2024 with Care Partnership – Diabetes and MetaDiab attended by around 120 clinicians. Feedback was consistently positive, and a follow-up Masterclass is planned.

3

Now it is being tested properly, here

eCARE does not assume the Western Sydney results will simply repeat. This trial measures how well a model proven in a metropolitan setting translates to rural and regional general practice, under real workforce and funding constraints — which is the only evidence that will persuade government to fund it permanently.

Safety, ethics and data

eCARE is approved by the Greater Western Human Research Ethics Committee. A clinical reporting committee of senior investigators oversees adverse events, and practices report any serious adverse event to the study team within 24 hours.

All study data is held securely in REDCap, a NSW Health approved system, with regular data quality checks. Findings are reported in aggregate, with no identifiable patient information.

Partners and contributors

eCARE depends on shared stewardship across Western Sydney Diabetes, WNSWLHD, the Western Diabetes Hub, Care Partnership – Diabetes, MetaDiab, the University of Sydney, private endocrinologists and participating general practices.

See the full partner list

Funding, and the question behind the question

Funded through a NSW Health Translational Research Grant and delivered with WNSWLHD and WNSW PHN, eCARE runs on a mixed funding model: MBS items, targeted reimbursements, public sector educator support, and industry-supported education, digital tools and CGM. Whether those levels are enough to sustain participation is itself an evaluation question — because a model that only works while a grant is running is not a model the system can adopt.

The trial is equally a test of whether the model builds lasting capability in the practice team — capability that should outlast the funding, and the trial itself.